Literature DB >> 20117916

Short and long interval cortical inhibition in patients with Unverricht-Lundborg and Lafora body disease.

Laura Canafoglia1, Claudia Ciano, Elisa Visani, Paola Anversa, Ferruccio Panzica, Maurizio Viri, Elena Gennaro, Federico Zara, Francesca Madia, Silvana Franceschetti.   

Abstract

Myoclonus has different clinical and neurophysiological features in patients with Unverricht-Lundborg (ULD) and Lafora body disease (LBD), probably because of a different cortical hyperexcitability profile. To investigate the role of intracortical inhibition in such different presentations, we used paired-pulse transcranial magnetic stimulation (TMS) in ten ULD and five LBD patients, all with a positive molecular diagnosis. All of the patients were treated with antiepileptic drugs (AEDs). In comparison with healthy subjects, both patient groups had significantly defective short intracortical inhibition (SICI), however LBD patients, but not ULD and healthy subjects, had a clear inhibition at ISI 6 ms and ISI 10 ms. Moreover, defective long interval cortical inhibition (LICI) was found in LBD but not ULD patients. The substantial reduction in SICI suggests that both ULD and LBD patients have impaired inhibitory interneuron pools which are involved in the generation of cortical reflex myoclonus, whereas the inhibition found in LBD patients at ISI 6 and 10 ms, as well the reduced inhibition found at long intervals, suggest a more complex circuitry dysfunction possibly involving both excitatory and inhibitory systems. These findings are probably related to the high epileptogenic propensity characterizing LBD with respect to ULD and to the more severely distorted neuronal network resulting from the pathogenesis of LBD. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20117916     DOI: 10.1016/j.eplepsyres.2010.01.006

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  6 in total

Review 1.  Lafora disease: epidemiology, pathophysiology and management.

Authors:  Thomas S Monaghan; Norman Delanty
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

Review 2.  Lafora disease.

Authors:  Julie Turnbull; Erica Tiberia; Pasquale Striano; Pierre Genton; Stirling Carpenter; Cameron A Ackerley; Berge A Minassian
Journal:  Epileptic Disord       Date:  2016-09-01       Impact factor: 1.819

3.  The network sustaining action myoclonus: a MEG-EMG study in patients with EPM1.

Authors:  Silvana Franceschetti; Laura Canafoglia; Fabio Rotondi; Elisa Visani; Alice Granvillano; Ferruccio Panzica
Journal:  BMC Neurol       Date:  2016-11-07       Impact factor: 2.474

4.  A Systematic Review of Long-Interval Intracortical Inhibition as a Biomarker in Neuropsychiatric Disorders.

Authors:  Parmis Fatih; M Utku Kucuker; Jennifer L Vande Voort; Deniz Doruk Camsari; Faranak Farzan; Paul E Croarkin
Journal:  Front Psychiatry       Date:  2021-06-02       Impact factor: 4.157

5.  Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease.

Authors:  Saida Ortolano; Irene Vieitez; Roberto Carlos Agis-Balboa; Carlos Spuch
Journal:  Mol Brain       Date:  2014-01-28       Impact factor: 4.041

Review 6.  Transcranial magnetic stimulation as a tool to understand genetic conditions associated with epilepsy.

Authors:  Katri Silvennoinen; Simona Balestrini; John C Rothwell; Sanjay M Sisodiya
Journal:  Epilepsia       Date:  2020-08-12       Impact factor: 6.740

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.